From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?
From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?
Created by
Presenter
Anne C. Goldberg, MD, FNLA, FACP, FAHA
Professor of Medicine Division of Endocrinology, Metabolism & Lipid Research Washington University in St. Louis St. Louis, MO